They include or originate from the abundant initial blood composition in platelets and / or growth factors and proteins in the initial blood composition, which are coagulated. Claim 10: according to the expression of claim 1, it is characterized by the inclusion of one or more biodegradable polymers selected from the following sources: hyaluronic acid, hyaluronate, tyrolidine 4 sulfate, tyrolidine 6 sulfuric acid, dextan, silica gel, hydrochloric acid, hydroxypropylmethylcellulose, chitin derivatives, Preferably chitosano, xantan rubber, agarosa； polyethylene glycerin (PEG),Polyhydroxyacrylic acrylonitrile (HEMA),Synthetic protein or natural protein 11. Claim 11: the expression in claim 1, which is characterized by including one or more organic polymers, selected from polygons, polygons, polygons and their polymers. 13. Claim 12: according to claim 1, it is characterized by including one or more of the following preparations: antibiotics, antibacterial agents, anticancer agents, painkillers, growth factors, hormones. Claim 14: method of preparation with appropriate biological or medical characteristics,characterized in that it comprises the steps of: a) having an initial blood composition, of human or animal origin, rich in platelets and / or growth factors； b) heating the initial blood composition at a temperature between 60 and 100 ° C for at least 1 minute； c) cool the initial blood composition for at least 1 minute.Formulación que comprende o se deriva de una composición sanguínea inicial rica en plaquetas y/o factores de crecimiento y proteínas provenientes de la propia composición sanguínea inicial, donde dichas proteínas se encuentran en estado gelificado. Reivindicación 10: Formulación según la reivindicación 1, caracterizada porque comprende uno o más polímeros biodegradables seleccionados entre: ácido hialurónico, sales de hialuronato, chondroitin 4 sulfato, chondroitin 6 sulfato, dextrán, gel de sílice, alginato, hidroxipropiImetilcelulosa, derivados de
